A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas
This clinical trial, sponsored by Dana-Farber Cancer Institute in collaboration with Genentech, investigates the safety and efficacy of Ado-trastuzumab emtansine (T-DM1) combined with standard chemoradiation in patients with HER2-positive salivary gland cancer. The trial aims to establish a treatment protocol for a cancer type lacking FDA-approved therapies.
Indication: Salivary Gland Cancer
Modality: monoclonal antibody
Target: HER2-positive Salivary Gland Carcinomas
Sponsor: Dana-Farber Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Apr 13, 2026
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: HER2-positive Salivary Gland Carcinomas
View original source fields
Condition raw: Salivary Gland Cancer, HER2 Gene Mutation
Condition normalized: Salivary Gland Cancer, HER2 Gene Mutation
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy
Target normalized: HER2-positive Salivary Gland Carcinomas